Show simple item record

dc.contributor.authorSaad, A A
dc.contributor.authorKassem, H S
dc.contributor.authorPovey, Andrew C
dc.contributor.authorMargison, Geoffrey P
dc.date.accessioned2010-11-17T13:02:02Z
dc.date.available2010-11-17T13:02:02Z
dc.date.issued2010
dc.identifier.citationExpression of O6-Alkylguanine-DNA Alkyltransferase in Normal and Malignant Bladder Tissue of Egyptian Patients. 2010, 2010:840230 J Nucleic Acidsen
dc.identifier.issn2090-021X
dc.identifier.pmid20981358
dc.identifier.doi10.4061/2010/840230
dc.identifier.urihttp://hdl.handle.net/10541/115711
dc.description.abstractBladder tumour tissues and corresponding uninvolved mucosa (normal tissue) of Egyptian bladder cancer patients were assessed for O(6)-alkylguanine-DNA-alkyltransferase (MGMT) activity by functional assay of tissue extracts (36 paired samples), and distribution by immunofluorescence (IF) microscopy of fixed material (24 paired samples). MGMT varied widely from 42-253 fmoles/mg protein and from 3.2-40 fmoles/μg DNA in normal and 58-468 fmoles/mg protein and 2.5-49.5 fmoles/mg protein, in the tumour tissues; only one tumour had undetectable activity. Pairwise comparison of MGMT activity in tumour and adjacent normal tissue showed no significant difference based on DNA content but was 1.75-fold higher in tumour (P < .01) based on protein. There was no effect of gender or bilharzia infection status. IF showed that in tumours, both the mean percentage of positive nuclei (57.3 ± 20.3%) and mean integrated IF (5.47 ± 3.66) were significantly higher than those in uninvolved tissues (42.8 ± 13.5% P = .04) and (1.89 ± 1.42; P < .01), respectively. These observations suggest that, overall, MGMT levels are increased during human bladder carcinogenesis and that MGMT downregulation is not a common feature of bladder cancers. Based on this, bladder cancers would be expected to be relatively resistant to chemotherapy which involved O(6)-guanine alkylating antitumour agents.
dc.language.isoenen
dc.subjectBladder Tumour Tissueen
dc.subjectBladder Canceren
dc.subjectEgyptian Malesen
dc.titleExpression of O6-Alkylguanine-DNA Alkyltransferase in Normal and Malignant Bladder Tissue of Egyptian Patients.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Carcinogenesis Group, Paterson Institute for Cancer Research, The University of Manchester, Manchester M20 4BX, UK.en
dc.identifier.journalJournal of Nucleic Acidsen
html.description.abstractBladder tumour tissues and corresponding uninvolved mucosa (normal tissue) of Egyptian bladder cancer patients were assessed for O(6)-alkylguanine-DNA-alkyltransferase (MGMT) activity by functional assay of tissue extracts (36 paired samples), and distribution by immunofluorescence (IF) microscopy of fixed material (24 paired samples). MGMT varied widely from 42-253 fmoles/mg protein and from 3.2-40 fmoles/μg DNA in normal and 58-468 fmoles/mg protein and 2.5-49.5 fmoles/mg protein, in the tumour tissues; only one tumour had undetectable activity. Pairwise comparison of MGMT activity in tumour and adjacent normal tissue showed no significant difference based on DNA content but was 1.75-fold higher in tumour (P < .01) based on protein. There was no effect of gender or bilharzia infection status. IF showed that in tumours, both the mean percentage of positive nuclei (57.3 ± 20.3%) and mean integrated IF (5.47 ± 3.66) were significantly higher than those in uninvolved tissues (42.8 ± 13.5% P = .04) and (1.89 ± 1.42; P < .01), respectively. These observations suggest that, overall, MGMT levels are increased during human bladder carcinogenesis and that MGMT downregulation is not a common feature of bladder cancers. Based on this, bladder cancers would be expected to be relatively resistant to chemotherapy which involved O(6)-guanine alkylating antitumour agents.


This item appears in the following Collection(s)

Show simple item record